Two Sigma Advisers
ACAD icon

Two Sigma Advisers’s Acadia Pharmaceuticals ACAD Stock Holding History

Two Sigma Advisers’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-370,200
Closed -$9.89M – 15
2025
Q4 		$9.89M Buy
370,200
+271,800
+276% +$6.5M 0.02% 547
2025
Q3 		$2.1M Sell
98,400
-96,500
-50% -$2.28M ﹤0.01% 1127
2025
Q2 		$4.2M Sell
194,900
-772,600
-80% -$14.4M 0.01% 798
2025
Q1 		$16.1M Sell
967,500
-295,700
-23% -$5.37M 0.04% 392
2024
Q4 		$23.2M Buy
1,263,200
+778,900
+161% +$12.6M 0.05% 278
2024
Q3 		$7.45M Buy
484,300
+428,900
+774% +$7.16M 0.02% 571
2024
Q2 		$900K Buy
55,400
+33,400
+152% +$539K ﹤0.01% 1599
2024
Q1 		$407K Sell
22,000
-47,600
-68% -$1.18M ﹤0.01% 1952
2023
Q4 		$2.18M Buy
69,600
+50,900
+272% +$1.22M 0.01% 1241
2023
Q3 		$390K Sell
18,700
-151,700
-89% -$4.12M ﹤0.01% 1882
2023
Q2 		$4.08M Buy
170,400
+158,100
+1,285% +$3.51M 0.01% 858
2023
Q1 		$231K Buy
+12,300
New +$234K ﹤0.01% 2226
2022
Q3 		– Sell
-16,600
Closed -$234K – 2522
2022
Q2 		$234K Sell
16,600
-40,300
-71% -$752K ﹤0.01% 2219
2022
Q1 		$1.38M Buy
+56,900
New +$1.38M ﹤0.01% 1462
2021
Q2 		– Sell
-189,500
Closed -$4.89M – 2421
2021
Q1 		$4.89M Sell
189,500
-233,100
-55% -$10.3M 0.01% 861
2020
Q4 		$22.6M Sell
422,600
-215,600
-34% -$10.7M 0.06% 320
2020
Q3 		$26.3M Buy
638,200
+238,100
+60% +$10.3M 0.08% 252
2020
Q2 		$19.4M Buy
400,100
+338,400
+548% +$16.2M 0.06% 334
2020
Q1 		$2.61M Sell
61,700
-43,100
-41% -$1.78M 0.01% 972
2019
Q4 		$4.48M Sell
104,800
-2,500
-2% -$109K 0.01% 885
2019
Q3 		$3.86M Buy
107,300
+36,000
+50% +$1.09M 0.01% 855
2019
Q2 		$1.91M Sell
71,300
-1,800
-2% -$46K ﹤0.01% 1230
2019
Q1 		$1.96M Buy
73,100
+18,600
+34% +$434K ﹤0.01% 1238
2018
Q4 		$881K Buy
+54,500
New +$1.06M ﹤0.01% 1540

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Two Sigma Advisers's ACAD Position: Q1 2026 in Review

Two Sigma Advisers sold out of Acadia Pharmaceuticals (ACAD) in Q1 2026, closing a stake of 370,200 shares — an estimated $9.89M sold.

Two Sigma Advisers first reported a position in ACAD in Q4 2018 and held it in 24 quarters. The position peaked at $26.3M in Q3 2020. 343 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

  • Two Sigma Advisers reported no remaining Acadia Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 370,200 Acadia Pharmaceuticals shares in Q1 2026, an estimated $9.89M.
  • Two Sigma Advisers first reported a position in Acadia Pharmaceuticals in Q4 2018 and held it in 24 quarters.
  • Two Sigma Advisers's Acadia Pharmaceuticals position peaked at $26.3M in Q3 2020.
  • 343 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.